Bristol Myers Squibb (CELG-RI) Finished Goods (2010 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Finished Goods of $569.0 million for Q1 2013, up 13.57% YoY from $501.0 million in Q1 2012, and down 0.52% sequentially from $572.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Finished Goods (2010 - 2013) Analysis & Trends
Bristol Myers Squibb has disclosed Finished Goods across 4 years of filings, most recently posting $569.0 million for Q1 2013.
- In Q1 2013, Finished Goods rose 13.57% year-over-year to $569.0 million; the TTM figure through Mar 2013 stood at $569.0 million (up 13.57% YoY), while the FY2012 annual figure was $572.0 million, up 19.67% from the prior year.
- Finished Goods fell to $569.0 million in Q1 2013, from $572.0 million in the prior quarter.
- Over the last five years, Finished Goods for CELG-RI reached as high as $572.0 million in Q4 2012 and fell as low as $397.0 million in Q4 2010.
- The 4-year median for Finished Goods is $489.5 million (2011), against an average of $484.7 million.
- Annual changes were most pronounced in 2012 — Finished Goods rose 21.01% — and 2013, when it increased 13.57%.
- A 4-year view of Finished Goods shows it stood at $397.0 million in 2010, then increased by 20.4% to $478.0 million in 2011, then advanced by 19.67% to $572.0 million in 2012, then decreased by 0.52% to $569.0 million in 2013.
- According to Business Quant data, Finished Goods over the past three periods registered $569.0 million, $572.0 million, and $533.0 million for Q1 2013, Q4 2012, and Q3 2012 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 569.00 Mn |
| Dec 31, 2012 | 572.00 Mn |
| Sep 30, 2012 | 533.00 Mn |
| Jun 30, 2012 | 503.00 Mn |
| Mar 31, 2012 | 501.00 Mn |
| Dec 31, 2011 | 478.00 Mn |
| Sep 30, 2011 | 443.00 Mn |
| Jun 30, 2011 | 437.00 Mn |
| Mar 31, 2011 | 414.00 Mn |
| Dec 31, 2010 | 397.00 Mn |